A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
Yonina R. Murciano-Goroff,Rebecca S. Heist,Yasutoshi Kuboki,Takafumi Koyama, Natraj Reddy Ammakkanavar,Antoine Hollebecque,Amita Patnaik,Toshio Shimizu, Alexander I. Spira,Misako Nagasaka,Ji-Youn Han,Wade Thomas Iams,Dustin Deming, Justin Call,Philippe Cassier,Sae-Won Han,Quincy Siu-Chung Chu, Rasha Cosman,Gregory Durm,Timothy Burns, Melinda D. Willard,Shiyao Liu, Sophie Callies,Arjun V. Balar,Joshua K. Sabari CANCER RESEARCH（2023）
AI 理解论文
溯源树
样例
